メインコンテンツにスキップ
検索

早期臨床

登録

最新のリソース

注目コンテンツ

Upcoming early clinical webinars

Latest early clinical blogs

医薬品開発におけるPK/PDモデリングのための機械学習
Machine Learning for PK/PD Modeling in Drug DevelopmentBlog

医薬品開発におけるPK/PDモデリングのための機械学習

米国FDAのモデルに基づく医薬品開発と対になったパイロットプログラムが治験依頼者を助ける方法
How the US FDA MIDD paired pilot program helps sponsorsBlog

米国FDAのモデルに基づく医薬品開発と対になったパイロットプログラムが治験依頼者を助ける方法

指標となる臨床的薬剤相互作用研究における代謝物の測定
Measuring metabolites in index clinical DDI studiesBlog

指標となる臨床的薬剤相互作用研究における代謝物の測定

Why FDA’s omaveloxolone approval for Friedreich’s ataxia matters
Why FDA’s omaveloxolone approval for Friedreich’s ataxia mattersBlog

Why FDA’s omaveloxolone approval for Friedreich’s ataxia matters

Key development considerations for cell therapies
Key development considerations for cell therapiesBlog

Key development considerations for cell therapies

医薬品開発のリスク軽減：早期開発における重要な化学、製造、および管理（CMC）および生理学的薬物動態（PBPK）アプローチ
De-risking Drug Development: Key Chemistry, Manufacturing, and Controls (CMC) and Physiologically Based Pharmacokinetic (PBPK) Approaches in Early Development Blog

医薬品開発のリスク軽減：早期開発における重要な化学、製造、および管理（CMC）および生理学的薬物動態（PBPK）アプローチ

以下のイベントで弊社のエキスパートをご紹介

All early clinical resources

Application of In Vitro-In Vivo Extrapolation (IVIVE) and Physiologically-based Pharmacokinetic Modeling to Investigate the Impact of the CYP2C8 Polymorphism on Rosiglitazone Exposure

Certara Products - Simcyp, Modeling and Simulation - PBPK, pre-update, Publication

Evaluation of an In Silico PBPK Postbariatric Surgery Model through Simulating Oral Drug Bioavailability of Atorvastatin and Cyclosporine

Model Informed Drug Development, pre-update, Publication

Characterizing Systemic Exposure of Inhaled Drugs: Application to the Long-acting β2-agonist PF-00610355

Model Informed Drug Development, Modeling and Simulation - PK/PD, pre-update, Publication

Age Related Changes in Fractional Elimination Pathways for Drugs: Assessing the Impact of Variable Ontogeny on Metabolic Drug-drug Interactions

Pediatrics, pre-update, Therapeutic Specialties, Publication

The Future of the Pharmaceutical Sciences and Graduate Education: Recommendations from the AACP Graduate Education Special Interest Group

Model Informed Drug Development, pre-update, Publication

Do Children Have the Same Vulnerability to Metabolic Drug-drug Interactions as Adults? A Critical Analysis of the Literature

Pediatrics, pre-update, Therapeutic Specialties, Publication

A Physiologically-based Pharmacokinetic Modeling Approach to Predict Disease-drug Interactions: Suppression of CYP3A by IL-6

Certara Products - Simcyp, Modeling and Simulation - PBPK, pre-update, Publication

Model-based Drug Development in Oncology: What’s Next?

Model Informed Drug Development, Modeling and Simulation - PK/PD, Oncology/Hematology, pre-update, Therapeutic Specialties, Publication

Model-supported Development of CS-8635: A Fixed-dose Combination of Olmesartan, Amlodipine, and Hydrochlorothiazide

Cardiovascular, Model Informed Drug Development, Modeling and Simulation - PK/PD, NLME (Non-Linear Mixed Effects), pre-update, Therapeutic Specialties, Publication

Predicting Drug-drug Interactions: Application of Physiologically-based Pharmacokinetic Models Under a Systems Biology Approach

Certara Products - Simcyp, Modeling and Simulation - PBPK, pre-update, Publication

In Vitro to Human In Vivo Translation—Pharmacokinetics and Pharmacodynamics of Quinidine

Model Informed Drug Development, pre-update, Publication

Systems Pharmacology of the Nerve Growth Factor Pathway: Use of a Systems Biology Model for the Identification of Key Drug Targets Using Sensitivity Analysis and the Integration of Physiology and Pharmacology

Central Nervous System (CNS), Model Informed Drug Development, Modeling and Simulation - QSP, pre-update, Therapeutic Specialties, Publication
ニュースレターを購読

今すぐ登録：医薬品開発の革新は、サターラの情熱そのものです。最新情報を入手し、ともに科学の限界を切り拓いていきましょう。


Powered by Translations.com GlobalLink Web Software